Quick Links
Doximity Plunges 20%+ on Weak Guidance: Leverage Liquidation Zones & Healthcare Tech Contagion
Data Snapshot
Key Takeaways
- •DOCS fell 19–22% in extended trading to $18.38–$18.81, driven by weak Q1/FY2026 guidance and AI compute cost margin erosion — not a revenue miss.
- •Leverage risk is extreme: a 50x long CFD at $23.52 would be liquidated before reaching $18.38; short-side traders captured up to 21.83% gains on the extended move.
- •Three major brokers cut price targets by 30–43% (Piper Sandler: $70→$40; Needham: $75→$55; Wells Fargo: $55→$45), signaling multi-quarter derating risk.
- •Cross-market spillover is limited — DOCS has minimal index weight — but digital health peers (TDOC, PHR, SOPH) face sympathy pressure on AI cost concerns.
- •RSI likely below 20 and FY2025 +20% revenue growth suggest an oversold bounce is possible; $18.00 is the critical support level and $20.00 the first resistance on any recovery.
Doximity (NYSE: DOCS) collapsed over 20% in after-hours trading on May 13–14, 2026, following its Q4 FY2025 earnings release. According to Benzinga, shares fell 19.58% after-hours to $18.81, while Mar
Event Summary
Doximity (NYSE: DOCS) collapsed over 20% in after-hours trading on May 13–14, 2026, following its Q4 FY2025 earnings release. According to Benzinga, shares fell 19.58% after-hours to $18.81, while MarketBeat reported an extended session decline of 21.83% to $18.38 — a potential 52-week low near November 2023 levels. The stock closed the regular session at $23.52, already down 11.10%.
The selloff is a classic earnings miss revenue shock dynamic: Doximity actually beat Q4 revenue estimates ($138.3–145.4M vs. consensus $134–144M) and delivered FY2025 revenue of $570.4M (+20% YoY), per Investing.com. However, soft Q1/FY2026 guidance and AI compute costs eroding gross margins were the primary catalysts. As reported by Investing.com, multiple brokers slashed price targets — Piper Sandler cut from $70 to $40 while maintaining Overweight, and Needham reduced from $75 to $55.
Leverage Impact Analysis
This is a high-volatility CFD event. CoinUnited.io offers stock CFDs with up to 2000x leverage and zero fees — making position sizing discipline critical here.
Scenario 1 — Long caught in the drop: A trader holding a 50x long DOCS CFD at $23.52 (regular close) with a $500 margin controls $25,000 notional. A 21.83% decline to $18.38 generates a $1,357 loss — wiping the position 2.7x over, triggering liquidation well before the lows. At 50x, a mere 2% adverse move (to ~$23.05) crosses a typical 100% margin threshold.
Scenario 2 — Short opportunity: Traders who entered short CFDs near the $23.52 close ahead of earnings captured the full 21.83% extended move. A 20x short with $1,000 margin controlling $20,000 notional would return ~$4,366 on the move to $18.38.
Key risk: Pre-market volatility of up to 35% (per Stocktwits) means slippage on market orders can be severe. Limit orders at defined levels ($18.38 extended low, $18.00 round-number support) are essential. Monitor implied volatility — the spike creates earnings miss recovery plays if the stock stabilizes near the $18–20 floor. For broader context on navigating these setups, see how to trade earnings misses.
Cross-Market Impact
This is a single-equity event with limited macro spillover, but sector contagion is real. Digital health peers — including Teladoc (TDOC), Phreesia (PHR), and SOPHiA Genetics (SOPH) — face sympathy pressure given shared exposure to AI compute cost inflation and regulatory risk in healthcare data.
At the index level, DOCS is a small-cap name with minimal weight in the NASDAQ 100 Index or S&P 500 Index, so direct index drag is negligible. However, the AI margin compression narrative — where AI capex is crimping profitability rather than boosting it — reinforces caution across the broader AI infrastructure capital reallocation theme that has pressured high-multiple tech names in 2026. No meaningful crypto, forex, or commodities linkage applies here.
Trading Considerations
Key levels to monitor: $18.38 (extended session low), $18.00 (round-number psychological support), and $20.00 (potential resistance on any bounce). The research report notes RSI is likely below 20 — deeply oversold territory that historically precedes tactical relief rallies, particularly given FY2025's strong +20% revenue growth and maintained 'Overweight' broker ratings.
Bears should watch for stabilization volume at the $18–19 zone as a signal of institutional accumulation. Bulls should require a confirmed close back above $20 before adding exposure — gap-fill attempts toward $23.52 represent the near-term upside target if guidance fears prove overdone.
Start Trading on CoinUnited.io
Create Your Free Account → — Trade crypto, stocks, forex, indices, and commodities with up to 2000x leverage and zero fees.
Frequently Asked Questions
Doximity's Q4 revenue beat consensus, but soft Q1/FY2026 guidance and AI compute costs compressing gross margins drove the selloff — investors price future earnings, not past beats.
Continue Exploring
Disclaimer: This brief is for educational purposes only and is not investment advice.